Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 7Plasma cell 3Sarcoma 2Myeloid 2Classical hematology 2Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Solid Tumors 1

Interventions

Injections 54pembrolizumab 40Carboplatin 20Bevacizumab 19Cyclophosphamide 17toripalimab 14Nivolumab 14Cisplatin 14tislelizumab 13fludarabine 13Specimen Handling 13Paclitaxel 13Interviews as Topic 13Pemetrexed 12Standard of Care 11Practice Guidelines as Topic 11Oxaliplatin 11Fluorouracil 10Cetuximab 10atezolizumab 9Educational Status 9Docetaxel 9Capecitabine 9Leucovorin 8Methods 7Etoposide 7Early Intervention, Educational 7spartalizumab 6olaparib 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × pegylated granulocyte colony-stimulating factor × Other solid neoplasm × Clear all
NCT06926751 2026-05-07

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
132 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡